Key Highlights

  • Zoetis received a USDA license for Cytopoint Plus for the treatment of allergic dermatitis in dogs.
  • The injection provides 75 days of allergic itch relief from a single dose.
  • The company says it is the longest treatment interval of any licensed monoclonal antibody for canine allergic dermatitis.
  • The license expands Zoetis’ canine dermatology portfolio alongside Cytopoint, Apoquel and Apoquel Chewable.

Zoetis Inc. (NYSE:ZTS) announced on November 11, 2026, that the United States Department of Agriculture has licensed Cytopoint Plus for the treatment of allergic dermatitis in dogs. The company said the product is the first and only USDA-licensed next-generation monoclonal antibody that provides 75 days of allergic itch relief in a single injection. The license adds a new option to the company’s range for managing chronic itch in dogs.

The announcement pitched the product as addressing a practical problem: the need for frequent clinic visits to keep dogs on treatment. Zoetis said the single-injection option removes the compliance barrier that visit schedules can create.

How Cytopoint Plus Changes Treatment

Allergic dermatitis can cause persistent itching that affects more than the skin. The company said chronic itch can disturb sleep, behavior and social interaction, and in some dogs it can cause touch sensitivity or signs of fear and anxiety. Managing those symptoms can create an ongoing burden for owners who must schedule regular treatment.

Because Cytopoint Plus lasts 75 days from a single injection, it extends the interval between treatments well beyond what many alternatives allow. For veterinary practices, that can reduce the number of visits needed, while owners can plan around fewer appointments in a year.

Where It Fits in the Zoetis Portfolio

The license adds to a canine dermatology range that already includes the original Cytopoint, Apoquel tablets and Apoquel Chewable. Zoetis said the portfolio now spans a fast-acting oral therapy through to the longest-acting injectable antibody, giving veterinarians several Options to match the treatment to the dog.

Abhay Nayak, executive vice president and president of U.S. commercial operations, said the license reflects the company’s commitment to improving the lives of animals and the people who care for them. The company presents the product as setting a new benchmark in canine dermatology, a claim that will be tested as veterinarians adopt it.

Market Context and Commercial Questions

Animal health is a competitive market, and dermatology is among its largest categories. A longer-acting option could help Zoetis defend share against rival treatments, but pricing, reimbursement and veterinarian preference will shape how much Revenue the product generates.

The announcement did not disclose sales expectations, pricing or launch timing. Investors will look for the rollout details and early uptake in the market to judge how much the license contributes to Zoetis’ growth in its companion animal business.

Final Word

Zoetis has received a USDA license for Cytopoint Plus, offering dog owners and veterinarians a monoclonal antibody that controls allergic itch for 75 days from one injection. The product extends the company’s canine dermatology lineup and reduces the need for frequent visits. Its commercial success will depend on adoption by veterinary practices and on how the market responds to the longer treatment interval.